Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles.

[1]  B. Plachter,et al.  Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. , 2002, Virology.

[2]  W. Britt,et al.  Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity , 2001, The New England journal of medicine.

[3]  M. Reddehase.  The immunogenicity of human and murine cytomegaloviruses. , 2000, Current opinion in immunology.

[4]  J. Harris,et al.  Dense Bodies of Human Cytomegalovirus Induce both Humoral and Cellular Immune Responses in the Absence of Viral Gene Expression , 2000, Journal of Virology.

[5]  W. Cox,et al.  Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. , 2000, The Journal of infectious diseases.

[6]  R. Sekulovich,et al.  Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. , 1999, The Journal of infectious diseases.

[7]  J. Schneider-Mergener,et al.  Target Structures of the CD8+-T-Cell Response to Human Cytomegalovirus: the 72-Kilodalton Major Immediate-Early Protein Revisited , 1999, Journal of Virology.

[8]  W. Britt,et al.  A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. , 1999, The Journal of infectious diseases.

[9]  G. Cathomas,et al.  Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. , 1999, The Journal of infectious diseases.

[10]  S. Plotkin.  Vaccination against cytomegalovirus, the changeling demon. , 1999, The Pediatric infectious disease journal.

[11]  H. Einsele,et al.  Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. , 1998, The Journal of infectious diseases.

[12]  R. Wiesner,et al.  Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. , 1998, Transplantation.

[13]  G. Geginat,et al.  Control of Murine Cytomegalovirus in the Lungs: Relative but Not Absolute Immunodominance of the Immediate-Early 1 Nonapeptide during the Antiviral Cytolytic T-Lymphocyte Response in Pulmonary Infiltrates , 1998, Journal of Virology.

[14]  J. Griffith,et al.  Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. , 1997, Clinical transplantation.

[15]  D. Snydman,et al.  Effect of Cytomegalovirus Infection Status on First-Year Mortality Rates among Orthotopic Liver Transplant Recipients , 1997, Annals of Internal Medicine.

[16]  J. Harris.  Negative staining and cryoelectron microscopy : the thin film techniques , 1997 .

[17]  X. Jin,et al.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL , 1996, Journal of virology.

[18]  T. Shenk,et al.  Proteins associated with purified human cytomegalovirus particles , 1996, Journal of virology.

[19]  W. Britt,et al.  Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. , 1996, Virology.

[20]  H. Kalbacher,et al.  Analysis of T helper cell response to glycoprotein H (gpUL75) of human cytomegalovirus: evidence for strain-specific T cell determinants. , 1996, The Journal of infectious diseases.

[21]  W. Britt,et al.  Human cytomegalovirus glycoproteins. , 1996, Intervirology.

[22]  W. Britt.  Vaccines against human cytomegalovirus: time to test. , 1996, Trends in microbiology.

[23]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[24]  D. Snydman,et al.  Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates , 1995, The Pediatric infectious disease journal.

[25]  E. Paoletti,et al.  Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate. , 1995, Vaccine.

[26]  M. Mach,et al.  Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. , 1995, The Journal of general virology.

[27]  S. Riddell,et al.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes , 1994, Journal of medical virology.

[28]  D. Snydman,et al.  Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study Group. , 1993, Transplantation proceedings.

[29]  W. Britt,et al.  The outcome of congenital cytomegalovirus infection in relation to maternal antibody status , 1992, The New England journal of medicine.

[30]  J. Scott,et al.  Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. , 1991, The Journal of infectious diseases.

[31]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[32]  W. Britt,et al.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. , 1991, Journal of immunology.

[33]  R. Rubin.  Impact of cytomegalovirus infection on organ transplant recipients. , 1990, Reviews of infectious diseases.

[34]  H. Friedman,et al.  Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. , 1989, The Journal of infectious diseases.

[35]  W. Britt,et al.  A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. , 1989, Journal of virological methods.

[36]  J. Sissons,et al.  Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses , 1988, The Journal of experimental medicine.

[37]  U. Koszinowski,et al.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity , 1987, Journal of virology.

[38]  S. Tonegawa,et al.  Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[39]  W. Gibson,et al.  Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. , 1983, Virology.

[40]  J. Manischewitz,et al.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. , 1982, The New England journal of medicine.

[41]  C. Prober,et al.  Prevention of transfusion-acquired cytomegalovirus infections in newborn infants , 1981 .